Based on these findings, we argue that the combination of FOXM1 inhibition and PARPi may prove an efficient therapeutic strategy for OC in the maintenance setting, due to its potential to synergistically interfere with OCSC-driven chemoresistance and tumor recurrence. The gene discussed is FOXM1; the disease is oral cavity squamous cell carcinoma.